Somatostatin and prostate cancer: role of somatostatin receptors in the control of tumor growth

Arvigo, Marica and Ruscica, Massimiliano and Albertelli, Manuela and Gatto, Federico and Cocchiara, Francesco and Roffredo, Laura and Minuto, Francesco and Magni, Paolo and Ferone, Diego (2013) Somatostatin and prostate cancer: role of somatostatin receptors in the control of tumor growth. Reviews in endocrinology and metabolism, 1 (1). pp. 2-10. ISSN 2282-8362

Preview

PDF -article2-10.pdf - Published Version Download (2MB)

Abstract

The evidence that prostate cancer (PCa) expresses specific receptors for hormones and neuropeptides, including somatostatin (SRIF) receptors (SSRs) has driven the research towards the identification of new potential diagnostic/therapeutic paths besides the conventional treatment options. Although the first attempts has led to inconclusive results due to the heterogeneity of this tumor and to the complex mechanisms involved in the progression of PCa tumor growth, the potential role of SRIF and its synthetic analogues (SSAs) in the treatment of PCa represents an “open challenge” in the light of the new knowledge about SSR pathophysiology. Indeed, SRIF and SSAs can control tumor cell proliferation by two separate mechanisms: a direct mechanism through the activation of the five specific SSRs or an indirect mechanism through the inhibition of secretion of several growth factors and hormones responsible for tumor cell proliferation. Since new SSAs specific for each receptor subtype, as well as bi-specific compounds and panligands have been synthetized, the identification of alternative SSR targets on PCa cells and the consequent employment of these new specific molecules in the treatment of advanced PCa (alone or in combination with traditional treatment options), could improve the prognosis particularly of those patients not responding to (anti-) hormonal therapy (hormone-refractory PCa patients).

Item Type:	Article
Uncontrolled Keywords:	Somatostatin receptors, prostate, cancer, tumor progression, octreotide, lanreotide
Subjects:	600 Tecnologia - Scienze applicate > 610 Medicina e salute (Classificare qui la tecnologia dei servizi medici) > 616 Malattie (classificare qui la Clinica medica, la medicina basata sull'evidenza, la Medicina interna, la Medicina sperimentale) > 616.4 Malattie del sistema emopoietico, linfatico, ghiandolare; Malattie del sistema endocrino
Depositing User:	Matteo Viola
Date Deposited:	17 Jun 2014 12:51
Last Modified:	17 Jun 2014 12:51
URI:	http://eprints.bice.rm.cnr.it/id/eprint/8522

Actions (login required)

View Item